Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nektar Therapeutics
Nektar Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Therapeutic: rezpegaldesleukin for dermatitis
Atopic dermatitis remains an unmet medical need, with better and more effective treatments still required for the one in 10 people who are affected
Regulatory
Anticancer agent – etirinotecan pegol
Nektar Therapeutics has developed a pegylated tetrameric derivative of irinotecan that is designed to preferentially penetrate tumour vasculature ahead of normal vasculature
Pharmaceutical
Ivan Gergel becomes SVP, Drug Development & Chief Medical Officer at Nektar Therapeutics
Joins the company from Endo Pharmaceuticals
Regulatory
Opioid-induced constipation – naloxegol
About half of all patients taking opioids commonly experience constipation
Subscribe now